RABEPK

Across TCGA pan-cancer cohorts, RABEPK mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RABEPK data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RABEPK mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RABEPK expression acts as an unfavorable survival marker.

PDAC, CCRCC, and GBM are the cancer types where RABEPK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.269	0.875	<.001	27	view →
CCRCC	OS	Tertile	II,III,IV	0.573	0.830	.011	8	view →
GBM	DFS	Quartile	All	0.616	0.773	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RABEPK–PDAC (OS)

Open the PDAC breakdown →